Live
FierceBiotechMadrigal continues MASH deal spree with $1B biobucks license for Arrowhead asset rejected by J&JEndpoints NewsSwiss manufacturing, biotech industry so far unfazed by geopoliticsEndpoints NewsPfizer ends Trillium-related development as R&D spend jumpsEndpoints NewsMicrobiome startup raises $48M for immunotherapy and malnutrition treatmentsEndpoints NewsJ&J's IBD combo fails Phase 2 studies, but will move into pivotal testingFierceBiotechPfizer’s $2.3B Trillium bet ends in failure as remaining CD47 blocker scrapped along with T-cell engagerFierceBiotechSanofi expands AI capabilities, investing $294M to scale Toronto hubEndpoints NewsMadrigal extends MASH deal streak with Arrowhead drug that J&J didn't wantEndpoints NewsHealthcare organizations are increasingly building their own AI toolsPharmaVoiceWhat’s at stake in Amgen’s showdown with the FDA?BioWorldGenosco discloses GSPT protein degradersBioWorldDeepcure develops new BRD4 BD2 inhibitors
BioPharma Dive Jan 21, 2026

Corvus shares nearly triple on positive data for eczema pill

Corvus shares nearly triple on positive data for eczema pill

Original
Body unavailable. Use the original source.